Mehmet Emin Büyükokuroğlu

Mehmet Emin Büyükokuroğlu

Auto-generated profile, based on publicly available information

Mehmet Emin Büyükokuroğlu

SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in International Journal of Surgery
Verified
Journal Article
Closed access
MKMetin Kement
Metin Kement
ZCZafer Censur
Zafer Censur
MOMustafa Oncel
Mustafa Oncel
MBMehmet E. Buyukokuroglu
Mehmet E. Buyukokuroglu
FGFazli C. Gezen
Fazli C. Gezen
This study aimed to assess the safety and effectiveness of different dosages of heparin for adhesion prevention by comparing with Seprafilm, in a murine model. Seventy five Balb/c mice were randomized into five groups. Group C were reserved as controls, and 62.5 IU, 125 IU, 250 IU of heparin, and Seprafilm were intraperitoneally applied in studied groups. The severity and locations of adhesions were assessed after the sacrification on day 14. The cause of death was investigated to evaluate the side effects of the drugs. The death of 2 subjects due to peritonitis (1 in Group C, 1 in Group H62.5) left 14 subjects in Group C and Group H62.5 (P ≥ 0.05), and no hemorrhage related death was observed. The use of the products significantly reduced the severity score of adhesion and the number of animals, had adhesions in different locations of the abdominal cavity, when the results were compared with the control group (P < 0.05 for all comparisons). Higher dosages of heparin seemed to be more effective. The results in group S, groups H250 and H125 were quite similar. Relatively high doses (125 IU and 250 IU) of intra-abdominal heparin may be comparable in safety and effectiveness to Seprafilm in adhesion prevention in mice.

1 January 2022 in The Eurasian Journal of Medicine
Verified
Journal Article
Open access
EYEmine Yanaşoğlu
Emine Yanaşoğlu
MBMustafa Büyükavcı
Mustafa Büyükavcı
AÇAyhan Çetinkaya
Ayhan Çetinkaya
GTGupse Turan
Gupse Turan
MKMehmet Köroğlu
Mehmet Köroğlu
MBMehmet Emin Büyükokuroğlu
Mehmet Emin Büyükokuroğlu
Objective: Hepatotoxicity is one of the major side effects of methotrexate and limits its use. In this study, we investigated the hepatoprotective effect of silibinin and the role of oxidative stress markers and cytokines on high-dose methotrexate-induced hepatotoxicity in rats. Materials and Methods: In this study, rats were randomly divided into 5 groups (n=7). Methotrexate (20 mg/kg, intraperitoneally) was administered on the first day in all groups except control. Silibinin was injected for 5 days to methotrexate–silibinin25, methotrexate–silibinin50, and methotrexate–silibinin100 groups at a dose of 25, 50, and 100 mg/kg/day, respectively. On the sixth day, blood and liver samples were obtained and rats were sacrificed. Serum total antioxidant capacity, total oxidant status, total thiol, native thiol, alanine aminotransferase, aspartate transaminase, bilirubin, albumin, tumor necrosis factor-alpha, and interleukin-10 levels were measured. In addition, a histopathological evaluation of liver tissues was performed. Results: Methotrexate reduced total antioxidant capacity and increased disulfide/total thiol ratio. Histopathologic examination revealed that methotrexate increased hepatic damage and 50 mg/kg/dose of silibinin prevented inflammatory cell infiltration in particular. Conclusion: Our results suggest that silibinin (50 mg/kg/day) may reduce the hepatic damage in methotrexate-induced hepatotoxicity in rats by increasing antioxidant capacity. Cite this article as: Yanaşoğlu E, Büyükavcı M, Çetinkaya A, et al. Silibinin effect on methotrexate-induced hepatotoxicity in rats. Eurasian J Med., 2022;54(3):264-269.

1 July 2010 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
MCMustafa Cemek
Mustafa Cemek
MBMehmet Emin Büyükokuroğlu
Mehmet Emin Büyükokuroğlu
Ahmet BüyükbenAhmet Büyükben
Ahmet Büyükben
FAFatih Aymelek
Fatih Aymelek
FYFatma Yılmaz
Fatma Yılmaz
DYDerya Yıldırım
Derya Yıldırım

1 January 2021 in Anais da Academia Brasileira de Ciências
Verified
Journal Article
Open access
MTMehmet H. Tanyeri
Mehmet H. Tanyeri
MBMehmet E. Buyukokuroglu
Mehmet E. Buyukokuroglu
PTPelin Tanyeri
Pelin Tanyeri
OMOguz Mutlu
Oguz Mutlu
AOAykut Ozturk
Aykut Ozturk
RKRumeysa K. Kaya
Rumeysa K. Kaya
Mirabegron is the first b3-adrenoceptor agonist to enter clinical practice and has been approved for the treatment of symptoms of OAB. The aim of this study is to investigate whether the mirabegron has an effect on depression, anxiety, learning, and memory. We investigated the effects of mirabegron on depression, anxiety, learning and memory by using forced swimming test, elevated plus maze test, passive avoidance and Morris water maze in mice. Imipramine and mirabegron (3, 6 and 9 mg/kg) significantly reduced immobility time in forced swimming test. Diazepam and mirabegron (3, 6 and 9 mg/kg) significantly increased the time spent in open arms and the number of entries to the open arms in elevated plus maze test. Furthermore, cognitive performance impaired with scopolamine has been significantly improved with 9 mg/kg mirabegron. Mirabegron (6 and 9 mg/kg) significantly increased the time spent in the target quadrant in naive mice. While scopolamine significantly increased the swimming speed, mirabegron (9 mg/kg) significantly decreased the swimming speed in scopolamine-treated mice. Mirabegron might be clinically useful for the treatment of OAB in elderly patients that should use drugs against depression and anxiety, without disrupt learning and memory.

30 September 2019 in Online Türk Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
MBMehmet Emin Büyükokuroğlu
Mehmet Emin Büyükokuroğlu
PTPelin Tanyeri̇
Pelin Tanyeri̇
RKRümeysa Keleş
Rümeysa Keleş
Çoklu ilaç tedavileri kaçınılmaz olarak ilaç-ilaç etkileşmelerine neden olabilmektedir. Bu durum ciddi sağlık sorunlarına yol açmakta ve hastaların zarar görmesi durumunda malpraktis açısından da hekimleri sorumlu hale getirmektedir. Çoklu ilaç tedavisi rejimleri her zaman için olumsuz etkileşme riskini taşırlar. Çoklu ilaç tedavisi rejimleri hem hekimleri bunaltmakta ve hem de olumsuz etkileşme riski taşımaları nedeniyle, bu tedavi rejimlerinin güvenliliğini sorgulanır hale getirmektedir. Bu yazıda, ilaç-ilaç etkileşmeleri hakkında genel bilgiler yanında önemli etkileşme örnekleri verilecektir. Yine makalemizde ilaç-ilaç etkileşmelerinin önlenmesine yönelik bazı öneriler yer alacaktır.

21 February 2022 in Sakarya Medical Journal
Verified
Journal Article
Open access
MTMehmet Hanifi Tanyeri̇
Mehmet Hanifi Tanyeri̇
MBMehmet Emin Büyükokuroğlu
Mehmet Emin Büyükokuroğlu
PTPelin Tanyeri̇
Pelin Tanyeri̇
AÖAykut Öztürk
Aykut Öztürk
RKRümeysa Keleş
Rümeysa Keleş
OMOguz Mutlu
Oguz Mutlu
Objective: Overactive bladder (OAB) constitutes the majority of childhood incontinence causes. Oxybutynin is an antimuscarinic agent frequently used for children in the treatment of OAB. This study aimed to investigate the effects of an antimuscarinic drug oxybutynin on learning and memory. Materials and Methods: We assessed the effects of oxybutynin on learning and memory functions using the Passive Avoidance (PA) and the Morris Water Maze (MWM) Test in mice. Results: Oxybutynin treatment (1 mg/kg, 2 mg/kg, and 4 mg/kg) did not show a significant difference in the retention time on the second day compared to the control and oxybutynin (4 mg/kg) significantly prolonged the retention time in scopolamine-treated mice. In the MWM Test, oxybutynin (1 mg/kg, 2 mg/kg, and 4 mg/kg) has no effect on the time spent in the target quadrant. Scopolamine (0.6 mg/kg) alone significantly reduced time spent in the target quadrant, but oxybutynin (4 mg/kg) significantly prolonged time spent in the target quadrant in scopolamine-treated mice. Also, scopolamine significantly increased the mean distance to the escape platform, while oxybutynin (4 mg/kg) significantly decreased the mean distance to the escape platform in scopolamine-treated mice. Conclusion: In our study, oxybutynin did not affect learning and memory, but it plays a role ameliorating the learning and memory deficits. The results of this study show that the use of oxybutynin in patients with OAB does not affect learning and memory.